JBIO 8-K: SEC filing

Filed with the SEC on Nov 13, 2026 · accession 0001193125-26-459287

JBIO filed a 8-K (current report) with the SEC on Nov 13, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Jade Biosciences, Inc. furnished a Form 8-K under Item 2.02 announcing its financial results for the quarter ended September 30, 2026, via a press release attached as Exhibit 99.1.

For details, click here →How to read a 8-K →

Key details

RegistrantJade Biosciences, Inc.

Chief financial officer and chief business officerBradford Dahms

✦ Ask GOAX AI about this filing — what it means for JBIO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for JBIO?

Click here

Frequently asked questions

What did JBIO file with the SEC on Nov 13, 2026?

JBIO filed a 8-K (SEC filing). Jade Biosciences, Inc. furnished a Form 8-K under Item 2.02 announcing its financial results for the quarter ended September 30, 2026, via a press release attached as Exhibit 99.1.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other JBIO SEC filings

Get alerts when JBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

JBIO overview JBIO analysis JBIO news Latest SEC filings